• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    argenx Appoints Karl Gubitz as Chief Financial Officer

    6/1/21 4:01:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARGX alert in real time by email



    June 1, 2021



    Breda, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced the appointment of Mr. Karl Gubitz as Chief Financial Officer. Mr. Gubitz brings to argenx nearly 20 years of global pharmaceutical leadership experience, specifically in financial planning and analysis, business partnerships and product commercialization. He will succeed Eric Castaldi, who will remain with the company through June 30, 2021.

    "We are delighted to welcome Karl to our executive leadership team as he has an impressive track record of successfully establishing commercial organizations and providing strategic financial direction for global biopharmaceutical companies," said Tim Van Hauwermeiren, CEO of argenx. "Karl's insight and financial expertise will make him an indispensable member of the team as we advance our vision of developing an integrated, innovative, global immunology organization that aims to impact the lives of patients."

    "On behalf of the argenx management team and Board of Directors, we thank Eric for his significant contributions as we have grown from a private company to a near-commercial organization. It has been a pleasure working with him and we are grateful for the integral role he played in our growth and success over the last seven years. He will always be a part of the argenx family and we wish him well in all his future ventures," added Mr. Van Hauwermeiren.

    Mr. Gubitz has nearly 20 years of experience as a senior finance professional in the pharmaceutical industry at Pfizer, where he most recently served as Vice President of Finance within the Global Oncology business. At Pfizer, he successfully negotiated the commercialization model for tanezumab with Eli Lilly in all non-U.S. markets as well as the Myovant co-commercialization agreement for Orgovyx™. Within Pfizer, Mr. Gubitz has held country, regional, and global positions, and consistently delivered top-line growth. He has managed teams of over 250 colleagues in roles such as Vice President of Finance in the Global Internal Medicine business and Vice President of Finance, North America in the Global Innovative Products business. Prior to joining Pfizer in 2003, Mr. Gubitz held various management roles at PricewaterhouseCoopers. Mr. Gubitz holds a Master of Business Administration from Henley Management College in the United Kingdom, a Bachelor of Computing from the University of South Africa, and a Bachelor of Commerce from the University of Pretoria.

    "This is a particularly exciting time to be joining argenx, as the Company nears the first potential commercial launch of its lead product, efgartigimod," said Mr. Gubitz. "I look forward to working alongside this talented team as we transition to a commercial-stage company and grow argenx's global immunology footprint to improve the lives of patients suffering from a variety of autoimmune diseases."

    About argenx

    argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit www.argenx.com and follow us on LinkedIn at https://www.linkedin.com/company/argenx/ and Twitter at https://twitter.com/argenxglobal.

    For further information, please contact:

    Media:

    Kelsey Kirk

    [email protected] 

    Joke Comijn 

    [email protected]

    Investors:

    Beth DelGiacco

    [email protected]

    Michelle Greenblatt

    [email protected]

    Forward-looking Statements

    The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should" and include statements argenx makes concerning its  commercial readiness; its hope to reach patients this year; its statements regarding the therapeutic potential of Efgartigimod in patients; 2021 business and financial outlook and related plans; the therapeutic potential of its product candidates; the intended results of its strategy and argenx's, and its collaboration partners', advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts; the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including the effects of the COVID-19 pandemic, argenx's expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product candidates; argenx's ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's limited operating history; and argenx's ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.



    Primary Logo

    Get the next $ARGX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ARGX

    DatePrice TargetRatingAnalyst
    7/8/2025Hold → Buy
    Deutsche Bank
    7/3/2025$700.00Overweight
    Morgan Stanley
    5/13/2025$680.00Neutral → Outperform
    Robert W. Baird
    3/17/2025Mkt Perform → Outperform
    Bernstein
    3/12/2025Sell → Hold
    Deutsche Bank
    1/17/2025Hold → Sell
    Deutsche Bank
    11/12/2024$697.00Peer Perform → Outperform
    Wolfe Research
    11/5/2024$715.00Sector Perform → Sector Outperform
    Scotiabank
    More analyst ratings

    $ARGX
    Leadership Updates

    Live Leadership Updates

    See more
    • argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

      January 16, 2023 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration f

      1/16/23 1:30:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Appoints Ana Cespedes to Board of Directors

      December 12, 2022 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors. Ana Cespedes brings robust experience across a broad range of critical areas for commercialization and access, as well as for organizational effectiveness. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.

      12/12/22 4:01:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Appoints Camilla Sylvest to Board of Directors

      September 8, 2022 Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors. Mrs. Sylvest brings strong strategic and operational leadership in the scaling of global commercial pharmaceutical organizations with a specific focus on company culture and sustainability. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.arg

      9/8/22 2:10:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Financials

    Live finance-specific insights

    See more
    • argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

      $949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional topline data readouts across pipeline remain on track for second half of 2025 Management to host conference call today at 2:30 PM CET (8:30 AM ET) July 31, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2025 results and provided a second quarter business up

      7/31/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

      July 24, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium                32 800 50

      7/24/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Reports First Quarter 2025 Financial Results and Provides Business Update

      $790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update. "We continue to execute on our bold innovation agenda, guided by our ‘V

      5/8/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    SEC Filings

    See more
    • SEC Form 6-K filed by argenx SE

      6-K - ARGENX SE (0001697862) (Filer)

      7/31/25 8:16:12 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by argenx SE

      6-K - ARGENX SE (0001697862) (Filer)

      6/30/25 7:49:57 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by argenx SE

      6-K - ARGENX SE (0001697862) (Filer)

      6/20/25 4:05:35 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • argenx upgraded by Deutsche Bank

      Deutsche Bank upgraded argenx from Hold to Buy

      7/8/25 8:21:40 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley resumed coverage on argenx with a new price target

      Morgan Stanley resumed coverage of argenx with a rating of Overweight and set a new price target of $700.00

      7/3/25 7:49:10 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded argenx from Neutral to Outperform and set a new price target of $680.00

      5/13/25 8:50:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

      $949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional topline data readouts across pipeline remain on track for second half of 2025 Management to host conference call today at 2:30 PM CET (8:30 AM ET) July 31, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2025 results and provided a second quarter business up

      7/31/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

      July 24, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium                32 800 50

      7/24/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

      Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model June 30, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to advance the clinical development of ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (Mu

      6/30/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by argenx SE

      SC 13G/A - ARGENX SE (0001697862) (Subject)

      11/14/24 1:22:37 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by argenx SE

      SC 13G/A - ARGENX SE (0001697862) (Subject)

      11/12/24 9:50:11 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by argenx SE (Amendment)

      SC 13G/A - ARGENX SE (0001697862) (Subject)

      2/14/24 10:03:02 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care